Effects of Pravastatin in the Elderly
Authors: Hiroshi Iwata, Tomonori Aoyama, Masahiro Kami
Journal: Annals of Internal Medicine (2002)

Letters4 June 2002Effects of Pravastatin in the ElderlyHiroshi Iwata, MD, Tomonori Aoyama, MD, and Masahiro Kami, MDHiroshi Iwata, MDToranomon HospitalTokyo 105-8470, JapanSearch for more papers by this author, Tomonori Aoyama, MDToranomon HospitalTokyo 105-8470, JapanSearch for more papers by this author, and Masahiro Kami, MDToranomon HospitalTokyo 105-8470, JapanSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-11-200206040-w2 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We would like to comment on Hunt and colleagues' subgroup analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial (1), especially the risk for cancer associated with long-term use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. A recent meta-analysis demonstrated no association between statin use over a 5-year period and risk for fatal and nonfatal cancer (2). However, this conclusion was limited because the follow-up of the studies analyzed was relatively short and incidence of cancer was not a primary objective. We believe that the true association between long-term use of HMG-CoA reductase inhibitors ...References1. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al . results from the LIPID trial. Ann Intern Med. 2001;134:931-40. [PMID: 11352694] LinkGoogle Scholar2. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716-23. [PMID: 11403756] CrossrefMedlineGoogle Scholar3. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-402. [PMID: 11100127] CrossrefMedlineGoogle Scholar4. Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al . Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-92. [PMID: 11385505] CrossrefMedlineGoogle Scholar5. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case–control study. Arch Intern Med. 2000;160:2363-8. [PMID: 10927735] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Toranomon HospitalTokyo 105-8470, Japan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBenefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial David Hunt , Peta Young , John Simes , Wendy Hague , Stewart Mann , Dwain Owensby , Geoffrey Lane , Andrew Tonkin , and Metrics 4 June 2002Volume 136, Issue 11Page: W2KeywordsCancer immunotherapyCancer treatmentDrugsElderlyHIV infectionsImmunosuppressivesLipidsLymphomaRelative riskStatins ePublished: 4 June 2002 Issue Published: 4 June 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.Loading ...